The CD44 Receptor is a Molecular Predictor of Survival in Ovarian Cancer

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2003 Sep 30

PMID 14514975

Citations 28

Authors

L Rodriguez-Rodriguez

I Sancho-Torres

C Mesonero

D G Gibbon

W J Shih

G Zotalis

Affiliations

Soon will be listed here.

Abstract

Purpose: CD44 is a cell surface receptor implicated in cancer progression and metastases. Malignant tumors may show a loss of CD44 splice control mechanisms. We investigated the role of CD44 splice variant expression in ovarian tumors and metastases, and its association with survival.

Experimental Design: We tested CD44 expression in 142 cases of epithelial carcinoma of the ovary and 265 metastatic sites by immunohistochemistry.

Results: Survival analysis showed that the expression of CD44s, CD44-v4, -v5, -v6, -v9, and -v10 are significant predictors for survival in univariate analysis. After stage, the expression of CD44-v10 in metastases was the strongest predictor of decreased survival in multivariate analysis (p = 0.0009). Conversely, CD44-v10 expression in the primary tumor was an independent predictor of improved survival in multivariate analysis (p = 0.0002). The expression of CD44s in the tumor/stroma interface of the primary tumor was associated with improved survival (p < 0.0001).

Conclusions: CD44 variant expression is a molecular prognostic maker for epithelial ovarian carcinomas. CD44-v10 expression is an independent prognostic indicator and the site of expression determines a positive or negative influence in survival. Our results also indicate that CD44 may be involved in important tumor/stroma interactions.

Citing Articles

The Prognostic Value of Cancer Stem Cell Markers (CSCs) Expression-ALDH1A1, CD133, CD44-For Survival and Long-Term Follow-Up of Ovarian Cancer Patients.

Izycka N, Rucinski M, Andrzejewska M, Szubert S, Nowak-Markwitz E, Sterzynska K Int J Mol Sci. 2023; 24(3).

PMID: 36768723 PMC: 9916537. DOI: 10.3390/ijms24032400.

Phase I trial of daily subcutaneous SPL-108 injections in combination with paclitaxel in patients with platinum resistant CD44+ advanced ovarian epithelial cancer.

Girda E, Hou J, Nelson D, Finlayson M, Buckley de Meritens A, Chekmareiva M Int J Gynecol Cancer. 2022; 32(8):1032-1038.

PMID: 35750354 PMC: 9380511. DOI: 10.1136/ijgc-2021-003316.

Aligned Collagen-CNT Nanofibrils and the Modulation Effect on Ovarian Cancer Cells.

Li W, Chi N, Clutter E, Zhu B, Wang R J Compos Sci. 2022; 5(6).

PMID: 35664989 PMC: 9164112. DOI: 10.3390/jcs5060148.

CD44 in Ovarian Cancer Progression and Therapy Resistance-A Critical Role for STAT3.

Martincuks A, Li P, Zhao Q, Zhang C, Li Y, Yu H Front Oncol. 2020; 10:589601.

PMID: 33335857 PMC: 7736609. DOI: 10.3389/fonc.2020.589601.

CD44 Expression Predicts Prognosis of Ovarian Cancer Patients Through Promoting Epithelial-Mesenchymal Transition (EMT) by Regulating Snail, ZEB1, and Caveolin-1.

Zhou J, Du Y, Lu Y, Luan B, Xu C, Yu Y Front Oncol. 2019; 9:802.

PMID: 31497537 PMC: 6712994. DOI: 10.3389/fonc.2019.00802.

References

Sancho-Torres I, Mesonero C, Miller Watelet J, Gibbon D, Rodriguez-Rodriguez L . Clear cell carcinoma of the ovary: characterization of its CD44 isoform repertoire. Gynecol Oncol. 2000; 79(2):187-95. DOI: 10.1006/gyno.2000.5938. View

Kohn E, Liotta L . Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res. 1995; 55(9):1856-62. View

Cannistra S, DeFranzo B, Niloff J, Ottensmeir C . Functional heterogeneity of CD44 molecules in ovarian cancer cell lines. Clin Cancer Res. 1995; 1(3):333-42. View

Goodison S, Tarin D . Current status of CD44 variant isoforms as cancer diagnostic markers. Histopathology. 1998; 32(1):1-6. DOI: 10.1046/j.1365-2559.1998.00262.x. View

Rosel M, Khaldoyanidi S, Zawadzki V, Zoller M . Involvement of CD44 variant isoform v10 in progenitor cell adhesion and maturation. Exp Hematol. 1999; 27(4):698-711. DOI: 10.1016/s0301-472x(98)00082-4. View

Gardner M, Jones L, Catterall J, Turner G . Expression of cell adhesion molecules on ovarian tumour cell lines and mesothelial cells, in relation to ovarian cancer metastasis. Cancer Lett. 1995; 91(2):229-34. DOI: 10.1016/0304-3835(95)03743-g. View

Saegusa M, Machida D, Hashimura M, Okayasu I . CD44 expression in benign, premalignant, and malignant ovarian neoplasms: relation to tumour development and progression. J Pathol. 1999; 189(3):326-37. DOI: 10.1002/(SICI)1096-9896(199911)189:3<326::AID-PATH425>3.0.CO;2-6. View

Darai E, Walker-Combrouze F, Fauconnier A, Madelenat P, POTET F, Scoazec J . Analysis of CD44 expression in serous and mucinous borderline tumours of the ovary: comparison with cystadenomas and overt carcinomas. Histopathology. 1998; 32(2):151-9. DOI: 10.1046/j.1365-2559.1998.00347.x. View

Lee T, Wisniewski H, Vilcek J . A novel secretory tumor necrosis factor-inducible protein (TSG-6) is a member of the family of hyaluronate binding proteins, closely related to the adhesion receptor CD44. J Cell Biol. 1992; 116(2):545-57. PMC: 2289279. DOI: 10.1083/jcb.116.2.545. View

10.

Levesque M, Haynes B . TNFalpha and IL-4 regulation of hyaluronan binding to monocyte CD44 involves posttranslational modification of CD44. Cell Immunol. 1999; 193(2):209-18. DOI: 10.1006/cimm.1999.1456. View

11.

Iida N, Bourguignon L . Coexpression of CD44 variant (v10/ex14) and CD44S in human mammary epithelial cells promotes tumorigenesis. J Cell Physiol. 1997; 171(2):152-60. DOI: 10.1002/(SICI)1097-4652(199705)171:2<152::AID-JCP5>3.0.CO;2-N. View

12.

Mackay C, Terpe H, Stauder R, Marston W, Stark H, Gunthert U . Expression and modulation of CD44 variant isoforms in humans. J Cell Biol. 1994; 124(1-2):71-82. PMC: 2119889. DOI: 10.1083/jcb.124.1.71. View

13.

Ross J, Sheehan C, Williams S, MALFETANO J, Szyfelbein W, Kallakury B . Decreased CD44 standard form expression correlates with prognostic variables in ovarian carcinomas. Am J Clin Pathol. 2001; 116(1):122-8. DOI: 10.1309/KUK0-1M3D-LGNE-THXR. View

14.

Rodriguez-Rodriguez L, Sancho-Torres I, Leakey P, Gibbon D, Comerci J, Ludlow J . CD44 splice variant expression in clear cell carcinoma of the ovary. Gynecol Oncol. 1998; 71(2):223-9. DOI: 10.1006/gyno.1998.5108. View

15.

Chiu R, Droll A, Dougherty S, Carpenito C, Cooper D, Dougherty G . Alternatively spliced CD44 isoforms containing exon v10 promote cellular adhesion through the recognition of chondroitin sulfate-modified CD44. Exp Cell Res. 1999; 248(1):314-21. DOI: 10.1006/excr.1999.4391. View